Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Silvia Salmoiraghi, Marie Lorena Guinea Montalvo, Elena D’Agostini, Giulia Amicarelli, Giulia Minnucci, Orietta Spinelli & Alessandro Rambaldi. (2013) Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. Expert Review of Hematology 6:4, pages 429-439.
Read now
Read now
Brian L Harry, S. Gail Eckhardt & Antonio Jimeno. (2012) JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opinion on Investigational Drugs 21:5, pages 637-655.
Read now
Read now
Mrinal M Patnaik & Ayalew Tefferi. (2009) Molecular diagnosis of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics 9:5, pages 481-492.
Read now
Read now
Ayalew Tefferi. (2008) JAK and MPL mutations in myeloid malignancies. Leukemia & Lymphoma 49:3, pages 388-397.
Read now
Read now
Stéphanie Poulain, Maud Merchez, Agnès Daudignon, Marc Simon, Patrick Duthilleul & Pierre Morel. (2006) JAK2 V617F mutation is absent in chronic lymphocytic leukemia. Leukemia & Lymphoma 47:12, pages 2657-2658.
Read now
Read now
Articles from other publishers (20)
Ayalew Tefferi. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1821
1835.e4
.
Natsuki Kajikawa, Yoshimoto Seki, Takayuki Fujio, Yasushi Okoshi, Mitsuo Hori, Hitoaki Saito, Tatsuo Iijima & Hiroshi Kojima. (2018) Central Nervous System Lymphoma Harboring the JAK2 V617F Mutation That Developed after a 20-year History of Polycythemia Vera. Internal Medicine 57:22, pages 3293-3297.
Crossref
Crossref
Ayalew Tefferi. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
14
.
Yordanka Tirefort, Xuan-Cuong Pham, Yasmine Lucile Ibrahim, Thomas Pierre Lecompte, Thomas Matthes, Christa Prins, Begonia Cortes, Michael Bernimoulin, Yves Chalandon & Kaveh Samii. (2014) A rare case of primary cutaneous follicle centre lymphoma presenting as a giant tumour of the scalp and combined with JAK2V617F positive essential thrombocythaemia. Biomarker Research 2:1.
Crossref
Crossref
Ayalew Tefferi. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1929
1943.e4
.
Gesa Hauck, Danny Jonigk, Hans Kreipe & Kais Hussein. (2013) Simultaneous and Sequential Concurrent Myeloproliferative and Lymphoproliferative Neoplasms. Acta Haematologica 129:3, pages 187-196.
Crossref
Crossref
R C T McKenzie, C L Jones, I Tosi, J A Caesar, S J Whittaker & T J Mitchell. (2011) Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1. Leukemia 26:2, pages 323-331.
Crossref
Crossref
Allison M. Cushman-Vokoun. 2012. Molecular Genetics and Personalized Medicine. Molecular Genetics and Personalized Medicine
51
101
.
Sebastian Ochsenreither, Mark Reinwald, Eckhard Thiel & Thomas Burmeister. (2012) Melting Point Assay for the JAK2 V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine. Molecular Diagnosis & Therapy 14:3, pages 185-190.
Crossref
Crossref
Cecile Meier, Sylvia Hoeller, Caroline Bourgau, Petra Hirschmann, Juerg Schwaller, Philip Went, Stefano A Pileri, Andreas Reiter, Stephan Dirnhofer & Alexandar Tzankov. (2009) Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Modern Pathology 22:3, pages 476-487.
Crossref
Crossref
Ayalew Tefferi. (2009) Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. Journal of Cellular and Molecular Medicine 13:2, pages 215-237.
Crossref
Crossref
Ayalew Tefferi, Ross L. Levine & Hagop Kantarjian. (2009) Oncogenic Signals as Treatment Targets in Classic Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation 15:1, pages 114-119.
Crossref
Crossref
Ayalew Tefferi. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
2261
2278
.
Ayalew Tefferi. (2007) JAK2 Mutations and Clinical Practice in Myeloproliferative Neoplasms. The Cancer Journal 13:6, pages 366-371.
Crossref
Crossref
Ayalew Tefferi. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
1
18
.
S. E. Langabeer, F. Ni Ainle, E. Conneally & M. Lawler. (2007) Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders. Irish Journal of Medical Science 176:2, pages 105-109.
Crossref
Crossref
Ayalew Tefferi & Animesh Pardanani. (2007) Evaluation of “Increased” Hemoglobin in the JAK2 Mutations Era: A Diagnostic Algorithm Based on Genetic Tests. Mayo Clinic Proceedings 82:5, pages 599-604.
Crossref
Crossref
Y. Lynn Wang, Joong W. Lee, Jonathan S. Kui, Amy Chadburn, Nicholas C.P. Cross, Daniel M. Knowles & Morton Coleman. (2007) Evaluation of <i>JAK2</i><sup>V617F</sup> in B and T Cell Neoplasms: Identification of <i>JAK2</i><sup>V617F</sup> Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals. Acta Haematologica 118:4, pages 209-214.
Crossref
Crossref
Ming CaoRandall J. OlsenYouli Zu. (2006) Polycythemia Vera: New Clinicopathologic Perspectives. Archives of Pathology & Laboratory Medicine 130:8, pages 1126-1132.
Crossref
Crossref
Ayalew Tefferi & Animesh Pardanani. (2006) Mutation screening for JAK2V617F: When to order the test and how to interpret the results. Leukemia Research 30:6, pages 739-744.
Crossref
Crossref